• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Refractory immune thrombocytopenia responding to combination therapy of eltrombopag and low-dose rituximab: a case series.

作者信息

Chu Tan-Huy, Huynh Thien-Ngon, Trinh-Le Quoc-Vu, Phu Chi-Dung

机构信息

Adult hematology department no.2, Blood Transfusion Hematology Hospital, Ho Chi Minh City, Vietnam; Department of Hematology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam.

Adult hematology department no.2, Blood Transfusion Hematology Hospital, Ho Chi Minh City, Vietnam.

出版信息

Hematol Transfus Cell Ther. 2024 Nov;46 Suppl 5(Suppl 5):S299-S304. doi: 10.1016/j.htct.2024.03.011. Epub 2024 Aug 18.

DOI:10.1016/j.htct.2024.03.011
PMID:39198048
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11670606/
Abstract
摘要

相似文献

1
Refractory immune thrombocytopenia responding to combination therapy of eltrombopag and low-dose rituximab: a case series.艾曲泊帕与低剂量利妥昔单抗联合治疗难治性免疫性血小板减少症：病例系列
Hematol Transfus Cell Ther. 2024 Nov;46 Suppl 5(Suppl 5):S299-S304. doi: 10.1016/j.htct.2024.03.011. Epub 2024 Aug 18.
2
Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain.在西班牙，用依洛尤单抗和利妥昔单抗治疗原发免疫性血小板减少症的成本-应答分析。
Farm Hosp. 2020 Oct 15;44(6):279-287. doi: 10.7399/fh.11525.
3
Steroid-Refractory Chronic Idiopathic Thrombocytopenic Purpura Responding to Combination Therapy With Eltrombopag and Rituximab.对艾曲泊帕和利妥昔单抗联合治疗有反应的类固醇难治性慢性特发性血小板减少性紫癜
Cureus. 2020 Sep 8;12(9):e10305. doi: 10.7759/cureus.10305.
4
Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients.高剂量地塞米松与泼尼松龙+硫唑嘌呤、利妥昔单抗、艾曲泊帕和罗米司亭治疗持续性、慢性、难治性和复发性免疫性血小板减少症患者的疗效比较
Pharmaceuticals (Basel). 2023 Aug 29;16(9):1215. doi: 10.3390/ph16091215.
5
Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.艾曲泊帕乙醇胺用于治疗一名非小细胞肺癌患者中由帕博利珠单抗诱导的难治性免疫相关性血小板减少症。
Lung Cancer. 2020 Aug;146:362-365. doi: 10.1016/j.lungcan.2020.05.015. Epub 2020 May 30.
6
Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag.大剂量脉冲环磷酰胺联合艾曲泊帕成功治疗重症难治性免疫性血小板减少症
Case Rep Hematol. 2015;2015:583451. doi: 10.1155/2015/583451. Epub 2015 Jun 9.
7
Chronic lymphocytic leukemia-associated refractory immune thrombocytopenia successfully treated with eltrombopag.艾曲泊帕成功治疗慢性淋巴细胞白血病相关难治性免疫性血小板减少症
Tumori. 2015 Apr 28;101(2):e49-50. doi: 10.5301/je.5000248.
8
Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.成人持续性免疫性血小板减少症的治疗效果：系统评价和网络荟萃分析。
Br J Haematol. 2020 Feb;188(3):450-459. doi: 10.1111/bjh.16161. Epub 2019 Aug 18.
9
Eltrombopag plus cyclosporine in refractory immune thrombocytopenia: a single-center study.艾曲泊帕联合环孢素治疗难治性免疫性血小板减少症：一项单中心研究。
Res Pract Thromb Haemost. 2023 Jun 14;7(5):100279. doi: 10.1016/j.rpth.2023.100279. eCollection 2023 Jul.
10
Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag A case series and literature review.狼疮相关性免疫性血小板减少症采用艾曲泊帕治疗的灾难性抗磷脂综合征：病例系列及文献复习。
Medicine (Baltimore). 2023 Feb 10;102(6):e32949. doi: 10.1097/MD.0000000000032949.

本文引用的文献

1
Immune Thrombocytopenia.免疫性血小板减少症
N Engl J Med. 2019 Sep 5;381(10):945-955. doi: 10.1056/NEJMcp1810479.
2
Immune Thrombocytopenia - Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, ÖGHO, SGH, GPOH, and DGTI.免疫性血小板减少症——当前的诊断与治疗：德国血液学和肿瘤学学会、奥地利血液学和肿瘤学学会、瑞士血液学和肿瘤学学会、德国儿科学会和德国血栓与止血学会联合工作组的建议
Oncol Res Treat. 2018;41 Suppl 5:1-30. doi: 10.1159/000492187. Epub 2018 Sep 19.
3
A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.
利妥昔单抗联合重组人血小板生成素对比利妥昔单抗治疗糖皮质激素抵抗或复发的免疫性血小板减少症的多中心随机开放标签研究
Blood. 2015 Mar 5;125(10):1541-7. doi: 10.1182/blood-2014-06-581868. Epub 2015 Jan 9.
4
Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.促血小板生成素治疗慢性免疫性血小板减少症患者的调节性 T 细胞活性增强。
Blood. 2010 Nov 25;116(22):4639-45. doi: 10.1182/blood-2010-04-281717. Epub 2010 Aug 5.
5
International consensus report on the investigation and management of primary immune thrombocytopenia.国际原发性免疫性血小板减少症诊治共识报告
Blood. 2010 Jan 14;115(2):168-86. doi: 10.1182/blood-2009-06-225565. Epub 2009 Oct 21.
6
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.成人及儿童免疫性血小板减少性紫癜术语、定义及疗效标准的标准化：国际工作组报告
Blood. 2009 Mar 12;113(11):2386-93. doi: 10.1182/blood-2008-07-162503. Epub 2008 Nov 12.
7
Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.利妥昔单抗治疗成年慢性免疫性血小板减少性紫癜脾切除候选者的疗效和安全性：一项前瞻性多中心2期研究结果
Blood. 2008 Aug 15;112(4):999-1004. doi: 10.1182/blood-2008-01-131029. Epub 2008 May 7.
8
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.低剂量利妥昔单抗对成人特发性血小板减少性紫癜患者有效。
Haematologica. 2008 Jun;93(6):930-3. doi: 10.3324/haematol.12206. Epub 2008 Apr 9.
9
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab.接受利妥昔单抗B细胞清除疗法的特发性血小板减少性紫癜患者调节性T细胞变化的分析
Blood. 2008 Aug 15;112(4):1147-50. doi: 10.1182/blood-2007-12-129262. Epub 2008 Mar 28.
10
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.利妥昔单抗（嵌合抗CD20单克隆抗体）治疗成人慢性特发性血小板减少性紫癜
Blood. 2001 Aug 15;98(4):952-7. doi: 10.1182/blood.v98.4.952.